Detection and analysis of ?-catenin mutations in prostate cancer
- 1 December 2000
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 45 (4) , 323-334
- https://doi.org/10.1002/1097-0045(20001201)45:4<323::aid-pros7>3.0.co;2-w
Abstract
E-cadherin and α-catenin are components of adherens junctions which mediate calcium-dependent, cell-cell adhesion in a homotypic manner. Both these molecules have been defined as useful tumor markers as their altered expression correlates with increased tumor aggressiveness and dedifferentiation. More recently, alterations of a third component of adherens junctions, β-catenin, have been observed to play a role in several human cancers. Dysregulation of β-catenin, either by direct mutation or by defects in interacting pathways/regulators, can result in its cytoplasmic accumulation and nuclear translocation. In the nucleus, β-catenin forms a transcriptional complex capable of upregulating target genes, many of which encode proliferative factors. Given its oncogenic activity and connection to human cancer, we examined the β-catenin gene and its expression in prostate cancer. By single-stranded conformational polymorphism (SSCP) and DNA sequencing analyses, we screened exon 3 of β-catenin from a panel of 81 primary tumors obtained at radical prostatectomy, 22 lymph node metastases from untreated patients, and a unique set of 61 metastatic tissues from 19 patients who died of hormone-refractory disease. We found putative activating mutations (missense and deletion) at a rate of 5% (7/138). One patient had the same 72 base pair deletion in each of nine separate metastases examined, indicating that this change was associated with a clonal population of metastatic cells. Immunohistological staining of mutation-positive tumors demonstrated β-catenin accumulation and nuclear localization in a heterogeneous fashion. Consistent with this in vivo finding, our in vitro analyses demonstrate that certain mutations can result in increased β-catenin nuclear activity in prostate cancer cell lines. These data implicate the β-catenin signaling pathway in the development of a subset of prostate cancers. Prostate 45:323–334, 2000.Keywords
This publication has 39 references indexed in Scilit:
- Regulation of β-Catenin Signaling by the B56 Subunit of Protein Phosphatase 2AScience, 1999
- The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cellPublished by Elsevier ,1999
- The oncogenic activation of β-cateninCurrent Opinion in Genetics & Development, 1999
- Prostate cancer: New therapies in the pipeline?Current Biology, 1998
- Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3βPublished by Elsevier ,1998
- Functional Interaction of an Axin Homolog, Conductin, with β-Catenin, APC, and GSK3βScience, 1998
- Stabilization of β-Catenin by Genetic Defects in Melanoma Cell LinesScience, 1997
- Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon CarcinomaScience, 1997
- Signal transduction through beta-catenin and specification of cell fate during embryogenesis.Genes & Development, 1996
- Cadherin Cell Adhesion Receptors as a Morphogenetic RegulatorScience, 1991